Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients

Postoperative Delirium After Living Donor Renal Transplantation Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02509949
• Other study ID #: DDRT
• Status: Recruiting
• Phase: Phase 4
• Start date: May 2015

Study information

• Verified date: June 2018
• Source: First Affiliated Hospital, Sun Yat-Sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Delirium, an acute change in mental status, is a serious medical complication among hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective disorders and cognitive disruptions.

One vulnerable period for developing delirium is in the postoperative days. Postoperative delirium often initiates a cascade of adverse consequences including an increase in length of stay and hospital costs, and greater mortality. The investigators have observed that the incidence of postoperative delirium in patients after renal transplantation is about 20-30% in our hospital.

Several studies have revealed that dexmedetomidine, as a widely used sedative during anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The investigators aim to examine whether administration of dexmedetomidine can reduce postoperative delirium after living donor renal transplantation in adult patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

• age > 17 and < 60 years;

• American Society of Anesthesiology (ASA) I-III;

• admitted for living donor renal transplantation.

Exclusion Criteria:

• Patients with a history of drug abuse;

• preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, inability to communicate in the preoperative period (coma, profound dementia, or language barrier).

Related Conditions & MeSH terms

• Delirium
• Postoperative Delirium After Living Donor Renal Transplantation

Intervention

Drug:
• Dexmedetomidine

• Saline

Locations

Country	Name	City	State
China	First Affiliated Hospital, Sun Yat-Sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Tao Zhang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postoperative Delirium		Postoperative day 1-7.